Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2015 and GOLD 2019 staging: a pooled analysis of individual patient data

In 2019, The Global Initiative for Chronic Obstructive Lung Disease (GOLD) modified the grading system for patients with COPD, creating 16 subgroups (1A–4D). As part of the COPD Cohorts Collaborative International Assessment (3CIA) initiative, we aim to compare the mortality prediction of the 2015 and 2019 COPD GOLD staging systems. We studied 17 139 COPD patients from the 3CIA study, selecting those with complete data. Patients were classified by the 2015 and 2019 GOLD ABCD systems, and we compared the predictive ability for 5-year mortality of both classifications. In total, 17 139 patients with COPD were enrolled in 22 cohorts from 11 countries between 2003 and 2017; 8823 of them had complete data and were analysed. Mean±sd age was 63.9±9.8 years and 62.9% were male. GOLD 2019 classified the patients in milder degrees of COPD. For both classifications, group D had higher mortality. 5-year mortality did not differ between groups B and C in GOLD 2015; in GOLD 2019, mortality was greater for group B than C. Patients classified as group A and B had better sensitivity and positive predictive value with the GOLD 2019 classification than GOLD 2015. GOLD 2015 had better sensitivity for group C and D than GOLD 2019. The area under the curve values for 5-year mortality were only 0.67 (95% CI 0.66–0.68) for GOLD 2015 and 0.65 (95% CI 0.63–0.66) for GOLD 2019. The new GOLD 2019 classification does not predict mortality better than the previous GOLD 2015 system. GOLD 2019 staging system created 16 subgroups. GOLD 2015 and GOLD 2019 are not strong predictors of mortality, and do not have sufficient discriminatory power to be used as a tool for risk classification of mortality in patients with COPD. https://bit.ly/3idBuaN

[1]  T. H. Nguyen,et al.  Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2020, The Lancet. Respiratory medicine.

[2]  N. Scichilone,et al.  Clinical and Functional Characteristics of COPD Patients Across GOLD Classifications: Results of a Multicenter Observational Study , 2019, COPD.

[3]  Ju-Young Kim,et al.  Validity of the GOLD 2017 classification in the prediction of mortality and respiratory hospitalization in patients with chronic obstructive pulmonary disease , 2019, International journal of chronic obstructive pulmonary disease.

[4]  J. Vestbo,et al.  Outcomes reported on the management of COPD exacerbations: a systematic survey of randomised controlled trials , 2019, ERJ Open Research.

[5]  Meilan K. Han,et al.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019 , 2019, European Respiratory Journal.

[6]  I. Arostegui,et al.  COPD classification models and mortality prediction capacity , 2019, International journal of chronic obstructive pulmonary disease.

[7]  E. Regan,et al.  Mortality and Exacerbations by Global Initiative for Chronic Obstructive Lung Disease Groups ABCD: 2011 Versus 2017 in the COPDGene® Cohort. , 2019, Chronic obstructive pulmonary diseases.

[8]  J. Soriano,et al.  External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CIAplus Cohort Study , 2019, COPD.

[9]  S. Yamanda,et al.  Clinical characteristics and outcomes in Japanese patients with COPD according to the 2017 GOLD classification: the Ishinomaki COPD Network Registry , 2018, International journal of chronic obstructive pulmonary disease.

[10]  T. MacDonald,et al.  The effect of changes to GOLD severity stage on long term morbidity and mortality in COPD , 2018, RESPIRATORY RESEARCH.

[11]  M. Miravitlles,et al.  Characteristics of COPD Patients Managed in Respiratory Medicine Departments in Spain, According to GOLD Groups and GesEPOC Clinical Phenotypes. , 2018, Archivos de bronconeumologia.

[12]  Tang-Hsiu Huang,et al.  Validation of the GOLD 2017 and new 16 subgroups (1A–4D) classifications in predicting exacerbation and mortality in COPD patients , 2018, International journal of chronic obstructive pulmonary disease.

[13]  R. Golpe,et al.  Mortality in COPD patients according to clinical phenotypes , 2018, International journal of chronic obstructive pulmonary disease.

[14]  Meilan K. Han,et al.  Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease , 2018, BMC Medicine.

[15]  E. Horváth-Puhó,et al.  Prediction of mortality in patients with chronic obstructive pulmonary disease with the new Global Initiative for Chronic Obstructive Lung Disease 2017 classification: a cohort study. , 2018, The Lancet. Respiratory medicine.

[16]  F. Maltais,et al.  Global Initiative for Chronic Obstructive Lung Disease 2017 Classification and Lung Function Decline in Chronic Obstructive Pulmonary Disease. , 2017, American journal of respiratory and critical care medicine.

[17]  M. Miravitlles,et al.  Characteristics of COPD Patients Managed in Respiratory Medicine Departments in Spain, According to GOLD Groups and GesEPOC Clinical Phenotypes. , 2018, Archivos de bronconeumologia.

[18]  Bernhard Kaiser,et al.  Multiple Score Comparison: a network meta-analysis approach to comparison and external validation of prognostic scores , 2017, BMC Medical Research Methodology.

[19]  M. Decramer,et al.  A simple algorithm for the identification of clinical COPD phenotypes , 2017, European Respiratory Journal.

[20]  T. H. Nguyen,et al.  Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2017, The Lancet. Respiratory medicine.

[21]  Alice M Turner,et al.  Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. , 2015, The Lancet. Respiratory medicine.

[22]  N. Metzdorf,et al.  Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial , 2014, BMC Pulmonary Medicine.

[23]  B. Celli,et al.  Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE , 2014, Thorax.

[24]  A. Gulsvik,et al.  Comparison of 2011 and 2007 Global Initiative for Chronic Obstructive Lung Disease guidelines for predicting mortality and hospitalization. , 2013, American journal of respiratory and critical care medicine.

[25]  L. Edwards,et al.  Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort , 2013, European Respiratory Journal.

[26]  Ciro Casanova,et al.  Distribution and prognostic validity of the new Global Initiative for Chronic Obstructive Lung Disease grading classification. , 2013, Chest.

[27]  Edwin K Silverman,et al.  GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. , 2013, The Lancet. Respiratory medicine.

[28]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[29]  J. Soriano,et al.  Multicomponent indices to predict survival in COPD: the COCOMICS study , 2012, European Respiratory Journal.

[30]  Morten Dahl,et al.  Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. , 2012, American journal of respiratory and critical care medicine.

[31]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[32]  Philip Marcus,et al.  Development of the asthma control test: a survey for assessing asthma control. , 2004, The Journal of allergy and clinical immunology.

[33]  R. Rodríguez-Roisín,et al.  Toward a consensus definition for COPD exacerbations. , 2000, Chest.

[34]  P. Jones,et al.  Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease , 1999, Thorax.